Alongside the suggestion of non-specific NOS inhibition in migraine therapeutics [94], preclinical studies suggest that targeting specific enzymes in the family may also hold promise without the unwanted side effects of targeting all the enzymes. This evidence concerns the gene NOS1 and migraine disorder.